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Abstract
Background: The aim of this study was to assess the
prognostic value of cancer antigen (CA) 125 and CA
72-4 in patients with ovarian borderline tumor (BOT).
Methods: All women diagnosed and treated for BOT
at our institution between 1981 and 2008 were includ-
ed into this retrospective study (ns101). Preopera-
tively collected serum samples were analyzed for CA
125 (Architect, Abbott and Elecsys, Roche) and CA 72-
4 (Elecsys, Roche) with reference to clinical data and
compared to healthy women (ns109) and ovarian
cancer patients (ns130).
Results: With a median of 34.7 U/mL (range 18.1–
385.0 U/mL) for CA 125 and 2.3 U/mL (range
0.2–277.0 U/mL) for CA 72-4, serum tumor markers in
BOT patients were significantly elevated as compared
to healthy women with a median CA 125 of 13.5
U/mL (range 4.0–49.7 U/mL) and median CA 72-4 of
0.8 U/mL (range 0.2–20.6 U/mL). In addition, there
was a significant difference compared with ovarian
cancer patients who showed a median CA 125 of
401.5 U/mL (range 12.5–35,813 U/mL), but no differ-
ence was observed for CA 72-4 (median 3.9 U/mL,
range 0.3–10,068 U/mL). Patients with a pT1a tumor
stage had significantly lower values of CA 125 but not
of CA 72-4 compared with individuals with higher
tumor stages (median CA 125 29.9 U/mL for pT1a vs.
50.9 U/mL for )pT1a; ps0.014). There was a trend
for increased concentrations of CA 125 but not of CA
72-4 in the presence of ascites, endometriosis or peri-
toneal implants at primary diagnosis. With respect to
the prognostic value of CA 125 or CA 72-4, CA 125
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was significantly higher at primary diagnosis in
patients who later developed recurrence (251.0 U/mL
vs. 34.65 U/mL, ps0.012).
Conclusions: Serum CA 125 and CA 72-4 concentra-
tions in BOT patients differ from healthy controls and
patients with ovarian cancer. CA 125, but not CA 72-
4, at primary diagnosis correlates with tumor stage
and tends to be increased in the presence of ascites,
endometriosis or peritoneal implants. Moreover, CA
125 at primary diagnosis appears to have prognostic
value for recurrence.
Clin Chem Lab Med 2009;47:537–42.
Keywords: biomarker; CA 125; CA 72-4; ovarian bor-
derline tumor (BOT); prognosis; tumor marker.
Introduction
Ovarian borderline tumors (BOT) account for
10%–20% of epithelial ovarian tumors (1). Often
described as a tumor of low malignant potential, it is
classified as a separate entity by the International
Federation of Gynecology and Obstetrics (2). It has an
incidence of 4.8/100,000 per year (3), and an excellent
clinical outcome reflected by 10-year survival rates of
;90% (4). Recurrence rates according to the literature
vary between 8% and 32% (5–9). Few studies have
analyzed risk factors for disease recurrence or prog-
nosis (9–11). Since borderline tumors of the ovary
have been described as showing late recurrence (12),
long-term follow-up is required to assess prognosis.
There is little information on the prognostic value
of preoperative tumor markers in BOT. It is known
that preoperative cancer antigen (CA) 125 concentra-
tions are increased in fewer patients with BOT com-
pared to ovarian cancer (13). In ovarian cancer, the
magnitude of increase in CA 125 is related to tumor
stage and histological subtype (14). In early ovarian
cancer, CA 125 concentrations at initial diagnosis
have been shown to be of prognostic value for sur-
vival (15). The aim of this study was to assess the
prognostic value of preoperative CA 125 and CA 72-4
in patients diagnosed with BOT.
Materials and methods
Patients
Study group I Since different methods for measurement of
CA 125 had been used over the long-time period that we
evaluated, two different study groups were established.
Study group I comprised healthy women, BOT and ovarian
cancer patients, and was used to validate the measurement
of tumor markers using different testing systems.
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In addition, the concentration of tumor markers in BOT
patients, patients with ovarian cancer and healthy women
were compared in this patient group. In total, this group con-
sisted of 16 patients diagnosed with a BOT, 130 patients with
ovarian cancer and 109 healthy women for whom blood
serum samples were available. Statistical evaluation of this
group assessed tumor marker concentrations, patient age,
menopause, tumor stage and histology.
Study group II All women diagnosed and treated for BOT
between 1981 and 2008 at our institution were included in
the retrospective analysis. A total of 160 patients treated for
BOT were identified. Of these 160 patients, tumor marker
concentrations had been measured preoperatively at our
institution in 101 patients, who were assigned to study group
II. For the remaining 59 patients, preoperative tumor marker
measurements were either not performed or had been done
outside our institution. Therefore, these patients were
excluded to ensure standardized analysis and comparability
of results. In the retrospective evaluation, tumor marker con-
centrations were evaluated with respect to patient charac-
teristics and clinical information including histology, tumor
stage, endometriosis, ascites, menopausal status, relapse
and survival.
Tumor markers Serum samples from patients included in
study group I had been stored at –808C. CA 72-4 (Elecsys,
Roche Diagnostics, Penzberg, Germany) and CA 125 (Archi-
tect, Abbott Diagnostics, Chicago, US and Elecsys, Roche
Diagnostics, Penzberg, Germany) were measured in patients
diagnosed with BOT (ns16), ovarian cancer (ns130) and
healthy women (ns109). CA 125 and CA 72-4 concentrations
for study group II had been measured at the time of primary
diagnosis using the kit in use at that time.
Histology All patients underwent surgery by experienced
gynecological surgeons at our institution. Typing and stag-
ing of tumors were performed by the Department of Patho-
logy according to the criteria of the International Federation
of Gynaecologists and Obstetricians (FIGO) and the Interna-
tional Union against Cancer (IUCC). Tumor, nodes, metas-
tases (TNM) and FIGO stage, World Health Organization
(WHO) grading and the presence of peritoneal implants were
recorded.
Follow-up Clinical data, demographic, diagnostic and treat-
ment information were obtained primarily from the patients’
charts. The following parameters were recorded for each
patient at initial diagnosis: age, menopausal status, and his-
tory of endometriosis.
During follow-up, patients were seen every 3 months fol-
lowing initial diagnosis for a period of three years, then at
six-month intervals for an additional two years, and then
once a year. Patients were evaluated sonographically for
signs of relapse and tumor markers were measured at each
follow-up visit. If a relapse was suspected (e.g., a persisting
suspicious adnexal mass found at sonography or a contin-
uous rise in tumor markers) surgery was performed to
achieve a histological diagnosis. The occurrence of relapse,
time to relapse, death and survival time were recorded. Dis-
ease recurrence and survival were the primary outcomes
assessed.
Statistics Statistical analysis was performed using SAS
V9.1 (SAS Institute Inc., Cary, NC, USA). Tumor marker con-
centrations are expressed as median and range. Differences
between subgroups of group I and II were evaluated using
the Wilcoxon test. For comparison of relapse and survival
times in group II, Kaplan-Meier curves were constructed.
Two groups were differentiated using median tumor marker
values as cut-off points, and the x2 statistic of the log-rank
test was calculated to test for differences between survival
curves. For regression analysis, the PHREG procedure was
performed based on the Cox proportional hazard model.
Tumor marker values were transformed to the logarithm
base 2 scale as predictors. p-Values -0.05 were considered
statistically significant.
Results
Study group I
Median age of patients at diagnosis of BOT was
59.6 years (range 23.6–88.3 years), for ovarian cancer
62.8 years (range 22.7–88.2 years). These reflect rep-
resentative ages for diagnosis of an ovarian border-
line or ovarian cancer. Median age for the group of
healthy women was 38.4 years (range 21.5–80.0
years). Due to the higher median age in the ovarian
cancer patients and BOT group, there was a higher
rate of postmenopausal women (81.3% in BOT, 78.5%
in ovarian cancer patients vs. 19.2% in healthy wom-
en). Histological stage was determined to be stage I
in 15 (93.8%) and stage III in one (6.2%) of the BOT
patients. For patients diagnosed with ovarian cancer,
22 (16.9%) had stage I disease, stage II in 15 (11.5%),
stage III in 83 (63.8%) and stage IV in 10 patients
(7.7%) (Table 1).
All samples were tested for CA 125 using two dif-
ferent test systems (Architect, Abbott and Elecsys,
Roche). Significantly different CA 125 concentrations
were observed between patients with a diagnosis of
ovarian cancer, BOT, and healthy women. Results for
BOT showed a median value of 34.7 U/mL (range
18.1–385 U/mL) measured with the Architect and
36.6 U/mL (range 17.3–332 U/mL) using the Elecsys
system. Results for CA 125 in BOT patients, obtained
using either system, were comparable and not statis-
tically different (p)0.05). However, for cancer
patients, median CA 125 was 401.5 U/mL (range
12.5–35,813 U/mL) with the Architect and 391.5 U/mL
(range 13–27,070 U/mL) with the Elecsys system
(p-0.001) (Table 1). Healthy women had a median CA
125 of 13.5 U/mL (range 4.0–49.7 U/mL) using the
Architect and 11.9 U/mL (range 3.2–68.8 U/mL) using
the Elecsys system (p-0.001). Interestingly, for both
tumor markers none of the patients diagnosed with
BOT or ovarian cancer had CA 125 levels below 10
U/mL, while more than 50% of healthy women
showed CA 125 levels below 10 U/mL.
Healthy women had significantly lower CA 72-4,
median 0.8 U/mL (range 0.2–20.6 U/mL), compared to
BOT and ovarian cancer patients (ps0.03) (Table 1).
There was no significant difference between CA 72-4
concentrations in patients with BOT (median 2.3
U/mL) and ovarian cancer (3.9 U/mL) (ps0.29).
Comparison of tumor marker concentrations meas-
ured in the same samples from individuals in group I
using the different test systems showed no significant
differences. Thus, the different testing systems used
for tumor marker measurement in group II over the
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Table 1 Patient characteristics of study group I comparing patients with BOT (borderline ovarian tumor), Ov CA (ovarian
cancer) and healthy women.
Patient characteristics BOT Ov CA Healthy women
n 16 130 109
Age (median), years 59.6 62.8 38.3
Premenopausal, % 18.7 21.5 80.2
Postmenopausal, % 81.3 78.5 19.8
Stage I, n 15 22
Stage II, n 0 15
Stage III, n 1 83
Stage IV, n 0 10
CA 125 U/mL (median, range)
Architect, Abbott 34.7 (18.1–385.0) 401.5 (12.5–35,813) 13.5 (4.0–49.7)
Elecsys, Roche 36.6 (17.3–332.0) 391.5 (13–27,070) 11.9 (3.2–68.8)
CA 72-4 U/mL (median, range)
Elecsys, Roche 2.3 (0.2–277) 3.9 (0.3–10068) 0.8 (0.2–20.6)
Table 2 Patient characteristics of study group II.
Patients, n 101
Age (median), years 53 years (range 18–88)
Menopausal stage, %
Premenopausal 61.5
Postmenopausal 38.5
Histology, %
Serous 63.0
Mucinous 36.3
Endometrioid 1.0
Tumor stage, %
pT1a 62.2
)pT1a 37.8
Ascites, % 10.8
Peritoneal implants, %
All 9.9
Invasive 8.9
Endometriosis, % 9.9
Follow-up (median) years 6.3"4.6 years
(minimum 3 months,
maximum 19.9 years)
Relapse, % 5.0
Deaths, % 5.0
years that this study encompassed should not have
any effect on the retrospective data evaluation of
group II study patients.
Study group II
Tumor marker measurements and surgery was per-
formed on 101 patients with BOT. Mean (SD) follow-
up time was 6.3 (4.6) years (minimum three months,
maximum 19.9 years). Relapse occurred during the
follow-up period in five patients (4.95%) with a mean
time to recurrence of 2.5 (16.0) years (minimum three
months, maximum 4.6 years). Five deaths (4.95%)
occurred, although it was not known if these were
tumor-related. Median age at primary diagnosis was
53 years (range 18–88 years) and 61.5% of patients
were premenopausal. Histology revealed a serous
tumor in 63% of patients, mucinous in 36%, and endo-
metrioid in one patient. Table 2 shows that 62.2% of
all patients were diagnosed at an early tumor stage
(pT1a).
Increased tumor marker concentrations were found
in 51.5% of BOT patients. Patients with increased CA
125 and CA 72-4 did not show any statistical differ-
ence with regard to menopausal status or histological
subtype (p)0.05) (Table 3). Patients with tumor stage
pT1a had significantly lower values for CA 125 but not
for CA 72-4 compared to those with higher tumor
stages (CA 125: 29.9 U/mL for pT1a vs. 50.9 U/mL for
higher stages; ps0.014; CA 72-4: 1.7 U/mL vs. 2.3
U/mL; ps0.165).
There was a trend for increased concentrations of
CA 125, but not of CA 72-4, in the presence of ascites
(CA 125, ps0.289; CA 72-4, ps0.686) endometriosis
(CA 125, ps0.116; CA 72-4, ps0.697) or peritoneal
implants (CA 125, ps0.057; CA 72-4, ps0.928) at pri-
mary diagnosis.
The prognostic value of CA 125 was significantly
higher at initial diagnosis in patients who later devel-
oped recurrent disease (251.0 U/mL vs. 34.65 U/mL,
ps0.012). Similar findings were also observed for CA
72-4 (ps0.093). Kaplan-Meier curves for CA 125 and
CA 72-4 revealed a significant relationship between
relapse and elevated CA 125 (Log-rank test, CA 125:
cut-off 35 U/mL, ps0.0368; CA 72-4: cut-off 1.9 U/mL,
ps0.0976) (Figures 1 and 2). Cox regression model
analysis showed the doubling of CA 125 to be asso-
ciated with a 2.261-fold risk of disease recurrence (CA
125: ps0.0039, hazard ratio (HR) 2.26, 95% HR confi-
dence interval (CI) 1.30–3.93; CA 72-4: ps0.1977, HR
1.27, 95% HR CI 0.88–1.82). However, no statistically
significant findings were found for overall survival.
Discussion
Information on the association of preoperative tumor
marker findings and BOT is very limited (16, 17). Stud-
ies of CA 125 have shown increased tumor marker
concentrations in BOT as well as in patients with ovar-
ian cancer (18). Our data confirm that serum CA 125
and CA 72-4 in patients with BOT differ in median val-
ues from healthy controls and patients with ovarian
cancer. The latter group generally shows the highest
concentration of CA 125 and CA 72-4; lowest concen-
trations seen in healthy women. Data from the liter-
ature suggest that the prevalence of BOT patients
with increased tumor marker concentrations varies
between 15% and 50% (19). These data are further
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Table 3 CA 125 and CA 72-4 concentrations according to menopausal stage, histology, tumor stage, presence of ascites,
peritoneal implants and endometriosis.
CA 125 U/mL (median, range) CA 72-4 U/mL (median, range)
Menopausal status
Premenopausal 36.9 (2.6–1996) 1.95 (0.4–396)
Postmenopausal 29.5 (7.3–418) ps0.668 2.0 (0.2–396) ps0.406
Histology
Serous 35.2 (2.6–1996) 1.7 (0.2–396)
Mucinous 36.1 (7.0–418) ps0.647 2.3 (0.2–277) ps0.243
Endometrioid 427.0 42.0
Tumor stage
pT1a 29.9 (2.6–454) 1.7 (0.2–230)
)pT1a 50.9 (7.3–1996) p-0.01a 2.3 (0.2–396) ps0.165
Ascites
Yes 62.8 (2.6–1996) 2.2 (0.5–396)
No 35.2 (7.0–418) ps0.029 1.9 (0.2–277) ps0.687
Implantation
Yes 122.5 (7.3–1996) 2.2 (0.2–396)
No 35.3 (2.6–529) ps0.06 1.85 (0.4–277) ps0.929
Endometriosis
Yes 98.6 (17.6–418) 1.7 (0.5–7.2)
No 35.3 (2.6–1996) ps0.12 2.0 (0.2–396) ps0.697
aStatistically significant.
Figure 1 Relapse-free patients with reference to CA 125.
Figure 2 Relapse-free patients with reference to CA 72-4.
supported by our study which showed tumor marker
increases in 51.5% of BOT patients. It has been pre-
viously reported that CA 125 is often not released in
patients with mucinous tumors (20), though our data
showed comparable results for mucinous and serous
tumors.
To date, the diagnosis of a BOT cannot be made
solely with CA 125 and CA 72-4 measurements
because of the considerable variability and overlap
between patients with ovarian cancer and healthy
individuals. We found that CA 125, but not CA 72-4,
correlates with tumor stage at initial diagnosis. Also
CA 125 tends to be increased in the presence of asci-
tes, endometriosis or peritoneal implants. Data from
the literature suggest that 80%–85% of patients with
advanced stages of ovarian cancer show increased
concentrations of CA 125, while only 50% with stage
I disease show such increases (14, 21).
Our findings may differ if results were interpreted
with respect to normal baseline values rather than
cut-off thresholds. Normally, baseline CA 125 and CA
72-4 measurements are not performed in healthy
women, making it difficult to test this hypothesis.
However, there are data showing that CA 125 levels
rise over time in patients with BOT, before the tumor
becomes clinically evident and is diagnosed (18).
Since we know that CA 125 and CA 72-4 concentra-
tions are increased in patients with BOT, knowledge
of a persistent increase in tumor marker concentra-
tions in these women might be helpful in establishing
a diagnosis. In addition, we have shown that CA 125
can be useful as a good negative predictor since all
patients diagnosed with BOT or ovarian cancer had
CA 125 levels above 10 U/mL, but more than 50% of
healthy women showed CA 125 levels below 10 U/mL.
This may be especially useful when confronted with
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unclear sonographic imaging findings where CA 125
can be useful for identifying patients at low-risk for
BOT or ovarian cancer.
The interpretation of increased tumor marker con-
centrations is still difficult because it is known to be
influenced by inflammation, endometriosis, liver dis-
ease, and ovulation, and also differs in pre- and post-
menopausal women (13, 22). The high rate of
false-positive results make interpretation of CA 125
and CA 72-4, alone, difficult in gynecological patients
(22). Therefore, combination with sonography and
clinical exam remains essential for diagnosis and
decision making.
Although, patients diagnosed with BOT generally
have a good prognosis, recurrence can occur. The
rate of recurrence in BOT is rather low, with a relapse
rate of 5% in this study group, compared to published
data showing rates of 15%–20% (23). At present, the
identification of patients at risk for recurrence of BOT
remains uncertain. Morice et al. found patients with
invasive implants to have higher relapse rates (11).
Our data show CA 125 elevation at initial diagnosis to
be of prognostic value for recurrence. Therefore, CA
125 and CA 72-4 in addition to being helpful in the
diagnosis of BOT, might even be useful for the iden-
tification of patients at risk for disease recurrence by
allowing appropriate follow-up intervals to be estab-
lished, since even late recurrence has been described
(12).
The role of tumor markers for early detection of dis-
ease recurrence during clinical follow-up remains dif-
ficult. Rustin et al. found that an increase in serum CA
125 to more than twice the upper limit of normal dur-
ing follow-up in patients with ovarian cancer after first
line chemotherapy accurately predicts tumor relapse
(24). Gotlieb et al., studying patients with BOT,
showed that increased concentrations of CA 125 can
indicate relapse, although increases did not occur in
all patients with relapse (16). Zanetta et al. described
increases in CA 125 above the cut-off in only 17% of
patients at the time of relapse (25). This finding is in
agreement with our data, as we also observed that
not all patients with recurrent disease showed an
increase in CA 125. However, it is not clear whether
early diagnosis of recurrent disease is of prognostic
advantage. Since better data are not available, clinical
examination, ultrasound and tumor marker measure-
ment remain the basis for clinical follow-up of
patients with BOT.
The strength of this study is the long-term follow-
up of patients (27 years), the high standard of surgery
by gynecologic oncologists at a specialized academic
institution and histopathologic review by expert gyne-
cologic oncology pathologists. A limitation is the ret-
rospective study design.
Conclusions
Serum CA 125 and 72-4 in patients with BOT differ in
median values from healthy controls and ovarian can-
cer patients. CA 125, but not CA 72-4, correlates with
tumor stage at initial diagnosis and tends to be
increased in the presence of ascites, endometriosis or
peritoneal implants. In addition, CA 125 concentra-
tions at initial diagnosis appear to have prognostic
value for disease recurrence. However, better analytic
tools for the detection of BOT are desirable.
References
1. Barakat RR. Borderline tumors of the ovary. Obstet
Gynecol Clin North Am 1994;21:93–105.
2. Scully RE. World Health Organization classification and
nomenclature of ovarian cancer. Natl Cancer Inst Mono-
gr 1975;42:5–7.
3. Trope C, Kaern J. Management of borderline tumors of
the ovary: state of the art. Semin Oncol 1998;25:372–80.
4. Trimble CL, Trimble EL. Management of epithelial ovar-
ian tumors of low malignant potential. Gynecol Oncol
1994;55:S52–61.
5. Kennedy AW, Hart WR. Ovarian papillary serous tumors
of low malignant potential (serous borderline tumors). A
long-term follow-up study, including patients with
microinvasion, lymph node metastasis, and transfor-
mation to invasive serous carcinoma. Cancer 1996;
78:278–86.
6. Crispens MA. Borderline ovarian tumours: a review of
the recent literature. Curr Opin Obstet Gynecol 2003;15:
39–43.
7. Lackman F, Carey MS, Kirk ME, McLachlin CM, Elit L.
Surgery as sole treatment for serous borderline tumors
of the ovary with non-invasive implants. Gynecol Oncol
2003;90:407–12.
8. Prat J, De Nictolis M. Serous borderline tumors of the
ovary: a long-term follow-up study of 137 cases, includ-
ing 18 with a micropapillary pattern and 20 with microin-
vasion. Am J Surg Pathol 2002;26:1111–28.
9. Seidman JD, Kurman RJ. Ovarian serous borderline
tumors: a critical review of the literature with emphasis
on prognostic indicators. Hum Pathol 2000;31:539–57.
10. Morice P, Camatte S, Rouzier R, Pautier P, Atallah D,
Pomel C, et al. wPrognostic factors and treatment for
advanced-stage borderline ovarian tumorsx. J Gynecol
Obstet Biol Reprod (Paris) 2002;31:623–8.
11. Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pau-
tier P, et al. Prognostic factors for patients with advanced
stage serous borderline tumours of the ovary. Ann Oncol
2003;14:592–8.
12. Silva EG, Gershenson DM, Malpica A, Deavers M. The
recurrence and the overall survival rates of ovarian
serous borderline neoplasms with non-invasive implants
is time dependent. Am J Surg Pathol 2006;30:1367–71.
13. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouil-
ly S. CA 125 in gynecological pathology – a review. Eur
J Obstet Gynecol Reprod Biol 1993;49:115–24.
14. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wil-
banks GD, Decker DG, et al. Adjuvant therapy in stage I
and stage II epithelial ovarian cancer. Results of two pro-
spective randomized trials. N Engl J Med 1990;322:
1021–7.
15. Paramasivam S, Tripcony L, Crandon A, Quinn M, Ham-
mond I, Marsden D, et al. Prognostic importance of
preoperative CA-125 in International Federation of Gyne-
cology and Obstetrics stage I epithelial ovarian cancer:
an Australian multicenter study. J Clin Oncol 2005;
23:5938–42.
16. Gotlieb WH, Soriano D, Achiron R, Zalel Y, Davidson B,
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 14.11.13 15:27
542 Lenhard et al.: Tumor markers in ovarian borderline tumors
Article in press - uncorrected proof
Kopolovic J, et al. CA 125 measurement and ultrasono-
graphy in borderline tumors of the ovary. Am J Obstet
Gynecol 2000;183:541–6.
17. van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP,
Cooper AL, McDonald JM, et al. Ovarian cancer screen-
ing with annual transvaginal sonography: findings of
25,000 women screened. Cancer 2007;109:1887–96.
18. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Ele-
vated serum CA 125 levels prior to diagnosis of ovarian
neoplasia: relevance for early detection of ovarian can-
cer. Int J Cancer 1988;42:677–80.
19. Buy JN, Ghossain MA, Sciot C, Bazot M, Guinet C, Prevot
S, et al. Epithelial tumors of the ovary: CT findings and
correlation with US. Radiology 1991;178:811–8.
20. Zurawski VR Jr, Knapp RC, Einhorn N, Kenemans P, Mor-
tel R, Ohmi K, et al. An initial analysis of preoperative
serum CA 125 levels in patients with early stage ovarian
carcinoma. Gynecol Oncol 1988;30:7–14.
21. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos
G, Torre GC, et al. CA125 in ovarian cancer: European
group on tumor markers guidelines for clinical use. Int
J Gynecol Cancer 2005;15:679–91.
22. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accu-
racy of CA 125 in the diagnosis of ovarian tumors: a
quantitative systematic review. Eur J Obstet Gynecol
Reprod Biol 2009;142:99–105.
23. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Man-
gioni C. Behavior of borderline tumors with particular
interest to persistence, recurrence, and progression to
invasive carcinoma: a prospective study. J Clin Oncol
2001;19:2658–64.
24. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining
progression of ovarian carcinoma during follow-up
according to CA 125: a North Thames Ovary Group
Study. Ann Oncol 1996;7:361–4.
25. Zanetta G, Rota S, Lissoni A, Meni A, Brancatelli G, Buda
A. Ultrasound, physical examination, and CA 125 meas-
urement for the detection of recurrence after conserva-
tive surgery for early borderline ovarian tumors.
Gynecol Oncol 2001;81:63–6.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 14.11.13 15:27
